Alex Toker

This study identifies BRD2 as a co-targetable vulnerability with PI3K/AKT inhibitors in breast cancer, showing that BRD2 phosphorylation is required for chromatin binding and that targeting BRD2 enhances drug efficacy.

This study shows that in prostate cancer with TMPRSS2:ERG fusion, androgen deprivation increases AKT activation, which may reduce the effectiveness of AR-targeted therapy, suggesting combination therapy could be beneficial.

This study shows that ALG3, a glycosyltransferase, is phosphorylated by AKT and regulates protein N-glycosylation, affecting cell proliferation and stress responses in cancer.

The paper identifies and validates tyrosine phosphorylation sites on metabolic enzymes using parallel phosphoproteomics and metabolomics in MCF10A cells.

This study identifies sex-specific metabolic reprogramming in obesity by analyzing phosphorylation sites on metabolic enzymes and their functional impact.

This study identifies a synergistic effect between AKT inhibitors and pitavastatin in killing triple-negative breast cancer cells by targeting cholesterol trafficking.